/ /

  • linkedin
  • Increase Font
  • Sharebar

    PCSK9 Inhibitors: A 5-Question Quiz


    Answer: A. True (with a caveat).

    The ODYSSEY-OUTCOMES trial, a prospective trial of ~18,000 patients after acute coronary syndrome (acute ischemic population) during treatment with alirocumab is expected to report results at the American College of Cardiology Conference in March 2018. However, outcome data are available from the FOURIER trial2 which reported on cardiovascular outcomes with the use of the evolcumab (Repatha, Amgen) in a secondary prevention population (stable CAD). At median follow up of 2.2 years, the results showed that there was a sustained reduction in LDL-C and a resulting reduction in the primary endpoint (composite of CVD, MI, stroke, hospitalization for unstable angina, or coronary revascularization) and the secondary endpoint (CVD, MI, stroke) with the benefit being driven primarily by reduction of non-fatal events such as stroke (lower by 0.4%), myocardial infarction (lower by 1.2%), coronary revascularization (lower by 1.5%). There was no mortality benefit. Some suggest that a mortality benefit may emerge with longer follow-up. No apparent safety signals emerged.

    Question 5.

    Payal Kohli, MD
    Payal Kohli, MD, is an attending cardiologist for Kaiser Permanente in Denver, Colorado.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available